Open on a desktop browser to explore the interactive map. The knowledge graph needs a larger screen and a pointer. On this device you are limited to the text below.
Dr. Ronald Roth Acu-Cell AI

Drug Class of Everolimus

  • Classification: Everolimus belongs to the class of medications known as mTOR inhibitors (mammalian target of rapamycin inhibitors).
  • Mechanism: It works by inhibiting the mTOR protein kinase, which plays a key role in regulating cell growth, division, and survival.
  • Application in HR-Positive Cancer: In hormone receptor-positive (HR+) breast cancer, it is typically used in combination with hormonal therapy (such as exemestane) to help overcome treatment resistance by targeting specific intracellular signaling pathways.
AI-generated in the approach of Dr. Ronald Roth. Not his own words.
Traversing graph…
Connections

Everolimus (Afinitor) - connections

Everolimus (Afinitor) ->

Antiglutamatergic drug - connections

-> Antiglutamatergic drug

HR-positive breast cancer - connections

-> HR-positive breast cancer

Overview
Loading graph...
Display TOP 100%
Loading full knowledge graph…
Building graph…
Preparing…
Filter by Relationship
Filter by Type
Some information may be incomplete, disputed, or incorrect. Review the supporting sources.